<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
<channel>
<title>Translational Medicine @ UniSa. Volume 18 (jan.-dec. 2018)</title>
<link>http://elea.unisa.it/xmlui/handle/10556/4514</link>
<description/>
<pubDate>Mon, 20 Apr 2026 10:02:36 GMT</pubDate>
<dc:date>2026-04-20T10:02:36Z</dc:date>
<item>
<title>Withholding and withdrawing in real life</title>
<link>http://elea.unisa.it/xmlui/handle/10556/4518</link>
<description>Withholding and withdrawing in real life
Piazza, Ornella
</description>
<pubDate>Mon, 01 Jan 2018 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://elea.unisa.it/xmlui/handle/10556/4518</guid>
<dc:date>2018-01-01T00:00:00Z</dc:date>
</item>
<item>
<title>Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients</title>
<link>http://elea.unisa.it/xmlui/handle/10556/4517</link>
<description>Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients
Bracale, Umberto Marcello; Di Filippo, Mathilde; De Capua, Antonio; Vanni, Linda; Narese, Donatella; Pecoraro, Felice; Giribono, Anna Maria; Bracale, Renata
Angioplasty with drug-coated balloon
(DCB) is an emerging and reliable method for the
treatment of femoro-popliteal lesions. We report
our experience with the Stellarex™ DCB in the
first 50 patients.
Methods - From July 2015 to November 2017, 50
patients (41 M, 9F), medium age (64 ± 7.4 year)
were subject to 33 angioplasties (PTAs) for
femoro-popliteal lesions with a paclitaxel-coated
balloon (Stellarex™). Based upon clinical data
sixteen patients had severe claudication (56% -
Rutherford class 3); ten patients suffered from
ischemic rest pain (34% - Rutherford class 4); and
five presented minor tissue loss (10% -
Rutherford class 5). 42% of patients showed
femoro-popliteal lesion TASC-II B, and 58%
presented lesions pertaining to TASC-II C.
Results - Immediate technical success was 100%
without perioperative complications. Primary
patency rate was 94% at twelve months. In three
cases restenosis (6%) was detected within a year
from procedure, and a further PTA DCB was
performed with primary assisted patency rates of
100% at twelve months. Two patients underwent
major lower limb amputation. Three patients died
during follow-up and one patient was lost at
follow-up.
Conclusion - DCB angioplasty with Stellarex™
is a viable alternative to traditional endovascular
procedures proving satisfactory primary patency
rates at twelve months. Based on our experience,
treatment with DCB is a first choice technique for
non-complex de novo lesions of the femoro –
popliteal tract.
</description>
<pubDate>Mon, 01 Jan 2018 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://elea.unisa.it/xmlui/handle/10556/4517</guid>
<dc:date>2018-01-01T00:00:00Z</dc:date>
</item>
</channel>
</rss>
